news
ELIQUIS® (apixaban) approved in Japan
26 December 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb and Pfizer Inc. announced that the Japanese Ministry of Health, Labor and Welfare has approved ELIQUIS® (apixaban)...
List view / Grid view
Pfizer
article
Intelligent Process Condition Monitoring for industrial tablet coating operation
18 December 2012 | By Jun Huang, Saly Romero-Torres, Liam Ryan and Mojgan Moshgbar, Pfizer Inc
This paper presents a feasibility study to develop an Intelligent Process Condition Monitoring (IPCM) system for providing a real time ‘health check’ for the tablet coating process in drug product manufacturing. The study fits well under the framework of Intelligent based Manufacturing (IbM) initiated at Pfizer, and intends to move…
news
ELIQUIS® (apixaban) demonstrated superiority in reducing a composite of recurrent venous thromboembolism and all-cause death without increasing the rate of major bleeding versus placebo during one year of extended treatment
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
news
Pfizer Acquires NextWave Pharmaceuticals, Inc.
28 November 2012 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc..
news
ELIQUIS® (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
news
Cystic Fibrosis Foundation Therapeutics announces $58 million CF drug discovery agreement with Pfizer
19 November 2012 | By Cystic Fibrosis Foundation
CFFT announced a major expansion of its research collaboration with Pfizer...
news
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release as treatment for patients with fibromyalgia
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
news
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation as adjunctive treatment in adult patients with partial onset seizures
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
news
Amgen and Pfizer highlight data to be presented at American College of Rheumatology Meeting
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
news
Auxilium and Pfizer will conclude agreement on XIAPEX® EU collaboration
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
news
U.S. Food and Drug Administration approves Pfizer’s XELJANZ® (tofacitinib citrate)
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
news
Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement
1 November 2012 | By Bristol-Myers Squibb Company
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a clinical collaboration agreement...
article
Non-Destructive Material Identification In-Depth Focus 2012
In this Non-Destructive Material Identification In-Depth Focus: An implementation perspective on handheld Raman spectrometers for the verification of material identity; Portable Raman spectroscopy for pharmaceutical counterfeit detection; Ask the Experts...
news
Pfizer’s XALKORI® receives conditional marketing authorization from the European Commission
24 October 2012 | By Pfizer
Conditional marketing authorization for XALKORI® in the EU granted...
news
Pfizer to acquire NextWave Pharmaceuticals, Inc.
22 October 2012 | By Pfizer
Pfizer has announced its intention to acquire NextWave Pharmaceuticals...
